Tag: Helix

  • Replacing dinner calcium with breakfast intake could reduce heart disease risk, study finds

    Replacing dinner calcium with breakfast intake could reduce heart disease risk, study finds

    [ad_1]

    In a recent study published in BMC Public Health, researchers investigated whether the quantity of calcium consumed at breakfast and dinner was associated with cardiovascular disease (CVD) in the general population.

    Study: Association of dietary calcium intake at dinner versus breakfast with cardiovascular disease in U.S. adults: the national health and nutrition examination survey, 2003–2018. Image Credit: Goskova Tatiana/Shutterstock.comStudy: Association of dietary calcium intake at dinner versus breakfast with cardiovascular disease in U.S. adults: the national health and nutrition examination survey, 2003–2018. Image Credit: Goskova Tatiana/Shutterstock.com

    Background

    Cardiovascular disease is the primary cause of mortality globally and the most prevalent chronic illness among individuals living in the United States.

    Calcium, a crucial dietary element, helps prevent and manage CVD by regulating blood vessels, muscular contraction, nerve transmission, hormone production, fat mass, blood pressure, and blood lipids. Circadian clocks in animals govern circadian rhythms, which are biological rhythmic patterns that last 24 hours.

    Diet is a significant external element that influences the synchronization of circadian clocks. Recent research indicates that calcium intake can influence physiological variations in circadian pacemaker-type neuronal cells and alter the expression of the biological clock genes.

    However, the relationship between calcium consumption at various times of the day and cardiovascular disease is unclear.

    About the study

    The present study examined the relationship between dietary calcium consumption at dinner and breakfast and CVD.

    The study comprised 36,164 United States individuals (17,456 males, 18,708 females, and 4,040 cardiovascular disease patients) from the 2013–2018 National Health and Nutrition Examination Surveys. They stratified the participants into five groups based on their calcium intakes from night and early morning meals.

    The study focused on the fraction of calcium consumption in night and morning meals (Δ=calcium intake from dinner /calcium intake from breakfast).

    The study’s endpoint was cardiovascular disease, based on a self-reported history of angina, heart failure, stroke, coronary artery disease, or heart attack.

    Potential confounders included age, sex, educational attainment, smoking status, physical activity, marital status, annual income, alcohol consumption, body mass index (BMI), high-density lipoprotein (HDL), uric acid (UA), total cholesterol (TC), hypertension, and type 2 diabetes (T2DM).

    Following confounder adjustment, the researchers used logistic regression to calculate the odds ratios (OR) for the relationship between the calcium intake percentage at night and morning and cardiovascular disease.

    They used dietary replacement models to investigate changes in cardiovascular disease risk by replacing 5.0% calcium from dinner with calcium consumption in the morning.

    The team conducted home interviews with individuals and collected data at a mobile testing facility. They excluded individuals under 20 years, pregnant women, those with incomplete data, those consuming more than 4,500 kcal per day, and those using calcium supplements.

    They assessed dietary consumption using a 24-hour diet recall completed on two non-consecutive days. They assessed nutrient intake using the Food and Nutrient Database for Dietary Studies recommendations by the United States Department of Agriculture. They performed sensitivity studies to investigate the validity of the study findings.

    Results and discussion

    Individuals in the uppermost quartile showed a higher likelihood of having cardiovascular disease than those in the lowermost quintile, with adjusted OR values of cardiovascular disease of 1.2.

    While keeping total calcium consumption constant, substituting a 5.0% calcium consumption from dinner meals with calcium consumption at breakfast reduced CVD risk by 6.0%.

    Breakfast meals with morning snacks or dinner meals with evening snacks reduced CVD risk by 6% (OR, 0.9). Compared to the lowermost quintile, having breakfast and morning snacks as breakfast or dinner and evening snacks as dinner in the uppermost Δ quintile significantly reduced CVD risk, with adjusted ORs of 1.1 and 1.1, respectively.

    Consuming dinner with evening snacks and breakfast with morning snacks yielded an adjusted OR of 1.1. Among overweight and obese individuals, the adjusted odds ratio of cardiovascular disease in the uppermost Δ quintile was 1.2 after adjusting for various confounding variables.

    The circadian clock governs several cardiovascular processes, including endothelial function, thrombus development, blood pressure, and heart rate. Basic helix-loop-helix ARNT-like protein 1 (Bmal1), a primary clock gene, regulates calcium absorption and metabolism.

    Sleep periods improve calcium retention capability. Circadian rhythm influences the inflammatory nuclear factor kappa B (NFκB) pathway, metabolism, and immune system adaptability.

    The study found that those in the top percentile of calcium consumption at dinner and breakfast are more likely to develop cardiovascular disease. The findings imply that allocating calcium intake to both meals is critical.

    The study demonstrated a positive correlation between the Δ value and cardiovascular disease risk. Replacing 5.0% of calcium consumption from dinner meals with the same amount at breakfast reduced CVD risk by 6.0%. However, further research is required to corroborate these findings across races and nations.

    [ad_2]

    Source link

  • Study reveals how DNA gyrase resolves DNA entanglements

    Study reveals how DNA gyrase resolves DNA entanglements

    [ad_1]

    Picture in your mind a traditional “landline” telephone with a coiled cord connecting the handset to the phone. The coiled telephone cord and the DNA double helix that stores the genetic material in every cell in the body have one thing in common; they both supercoil, or coil about themselves, and tangle in ways that can be difficult to undo. In the case of DNA, if this overwinding is not dealt with, essential processes such as copying DNA and cell division grind to a halt. Fortunately, cells have an ingenious solution to carefully regulate DNA supercoiling.

    In this study published in the journal Science, researchers at Baylor College of Medicine, Université de Strasbourg, Université Paris Cité and collaborating institutions reveal how DNA gyrase resolves DNA entanglements. The findings not only provide novel insights into this fundamental biological mechanism but also have potential practical applications. Gyrases are biomedical targets for the treatment of bacterial infections and the similar human versions of the enzymes are targets for many anti-cancer drugs. Better understanding of how gyrases work at the molecular level can potentially improve clinical treatments.

    Some DNA supercoiling is essential to make DNA accessible to allow the cell to read and make copies of the genetic information, but either too little or too much supercoiling is detrimental. For example, the act of copying and reading DNA overwinds it ahead of the enzymes that read and copy the genetic code, interrupting the process. It’s long been known that DNA gyrase plays a role in untangling the overwinding, but the details were not clear.

    DNA minicircles and advanced imaging techniques reveal first step to untangle DNA

    We typically picture DNA as the straight double helix structure, but inside cells, DNA exists in supercoiled loops. Understanding the molecular interactions between the supercoils and the enzymes that participate in DNA functions has been technically challenging, so we typically use linear DNA molecules instead of coiled DNA to study the interactions. One goal of our laboratory has been to study these interactions using a DNA structure that more closely mimics the actual supercoiled and looped DNA form present in living cells.”


    Dr. Lynn Zechiedrich, study author, Kyle and Josephine Morrow Chair in Molecular Virology and Microbiology and professor of the Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology at Baylor College of Medicine

    After years of work, the Zechiedrich lab has created small loops of supercoiled DNA. In essence, they took the familiar straight linear DNA double helix and twisted it in either direction once, twice, three times or more and connected the ends together to form a loop. Their previous study looking at the 3-D structures of the resulting supercoiled minicircles revealed that these loops form a variety of shapes that they hypothesized enzymes such as gyrase would recognize.

    In the current study, their hypothesis was proven correct. The team of researchers combined their expertise to study the interactions of DNA gyrase with DNA minicircles using recent technology advances in electron cryomicroscopy, an imaging technique that produces high-resolution 3-D views of large molecules, and other technologies.

    “My lab has long been interested in understanding how molecular nanomachines operate in the cell. We have been studying DNA gyrases, very large enzymes that regulate DNA supercoiling,” said co-corresponding author Dr. Valérie Lamour, associate professor at the Institut de Génétique et de Biologie Moléculaire et Cellulaire, Université de Strasbourg. “Among other functions, supercoiling is the cell’s way of confining about 2 meters (6.6 feet) of linear DNA into the microscopic nucleus of the cell.”

    As the DNA supercoils inside the nucleus, it twists and folds in different forms. Imagine twisting that telephone cord mentioned at the beginning, several times on itself. It will overwind and form a loop by crossing over DNA chains, tightening the structure.

    “We found, just as we had hypothesized, that gyrase is attracted to the supercoiled minicircle and places itself in the inside of this supercoiled loop,” said co-author, Dr. Jonathan Fogg, senior staff scientist of molecular virology and microbiology, and biochemistry and molecular pharmacology in the Zechiedrich lab.

    “This is the first step of the mechanism that prompts the enzyme for resolving DNA entanglements,” Lamour said.

    “DNA gyrase, now surrounded by a tightly supercoiled loop, will cut one DNA helix in the loop, pass the other DNA helix through the cut in the other, and reseal the break, which relaxes the overwinding and eases the tangles, regulating DNA supercoiling to control DNA activity,” Zechiedrich said. “Imagine watching the rodeo. Like roping cattle with a lasso, supercoiled looped DNA captures gyrase in the first step. Gyrase then cuts one double-helix of the DNA lasso and passes the other helix through the break to get free.”

    Co-corresponding author, Dr. Marc Nadal, professor at the École Normale in Paris confirmed the observation of the path of the DNA wrapped in the loop around gyrase using magnetic tweezers, a biophysical technique that allows to measure the deformation and fluctuations in the length of a single molecule of DNA. Observing a single molecule provides information that is often obscured when looking at thousands of molecules in traditional so-called “ensemble” experiments in a test tube.

    Interestingly, the “DNA strand inversion model” for gyrase activity was proposed in 1979 by Drs. Patrick O. Brown and the late Nicholas R. Cozzarelli, also in a Science paper, well before researchers had access to supercoiled minicircles or the 3-D molecular structure of the enzyme. “It’s especially meaningful to me that 45 years later, we finally provide experimental evidence supporting their hypothesis because Nick was my postdoctoral mentor,” Zechiedrich said.

    “This work opens a myriad of perspectives to study the mechanism of this conserved class of enzymes, which are of great clinical value,” Lamour said.

    “This work supports new ideas on how DNA activities are regulated. We propose that DNA is not a passive biomolecule acted upon by enzymes, but an active one that uses supercoiling, looping and 3-D shapes to direct accessibility of enzymes such as gyrase to specific DNA sequences in a variety of situations, which will likely impact cellular responses to antibiotics or other treatments,” Fogg said.

    Contributors to this work also include Marlène Vayssières (lead author), Nils Marechal, Long Yun, Brian Lopez Duran and Naveen Kumar Murugasamy. The authors are affiliated with one or more of the following institutions: Baylor College of Medicine, Université de Strasbourg, Institut de Génétique et de Biologie Moléculaire et Cellulaire, INSERM, Université Paris and Hôpitaux Universitaires de Strasbourg.

    Source:

    Journal reference:

    Vayssières, M., et al. (2024) Structural basis of DNA crossover capture by Escherichia coli DNA gyrase. Science. doi.org/10.1126/science.adl5899.

    [ad_2]

    Source link

  • Enhancing the safety and efficacy of breast and ovarian cancer treatment

    Enhancing the safety and efficacy of breast and ovarian cancer treatment

    [ad_1]

    Some anti-cancer treatments not only target tumor cells but also healthy cells. If their effects on the latter are too strong, their use can become limiting. A team from the University of Geneva (UNIGE), in collaboration with Basel-based FoRx Therapeutics, has identified the mechanism of action of PARP inhibitors, used in particular for breast and ovarian cancer in patients carrying the BRCA gene mutation. These inhibitors block two specific activities of the PARP proteins. By blocking one of them, the toxic effect on cancer cells is maintained, while healthy cells are preserved. This work, published in the journal Nature, will help improve the efficacy of these treatments. 

    Despite the thousands of lesions that damage our DNA every day, the genome of our cells is particularly stable thanks to a highly efficient repair system. Among the genes coding for repair proteins are BRCA1 and BRCA2 (for BReast CAncer 1 and 2), which are particularly involved in DNA double helix breaks. The presence of mutations in these genes (in around 2 out of every 1,000 women) can result in non-repair of damaged DNA, and greatly increase the risk of developing breast or ovarian cancer (or prostate cancer in men).

    Non-cancerous cells killed by treatments

    PARP inhibitors have been used to treat this type of cancer for around 15 years. PARP proteins can detect breaks or abnormal structures in the DNA double helix. PARPs then temporarily stick to the DNA, synthesizing a chain of sugars which acts as an alarm signal to recruit the proteins involved in DNA repair. Treatments based on PARP inhibitors block these activities and trap the PARP protein on the DNA. There is then no alarm signal to trigger DNA repair.

    This treatment proves toxic for fast-growing cells such as cancer cells, which generate too many mutations without having time to repair them and are thus doomed to die. But our bodies are also home to fast-growing healthy cells. This is the case, for example, of hematopoietic cells – the source of red and white blood cells – which, as collateral victims, are also massively destroyed by anti-PARP treatments.

    The mechanisms by which anti-PARP drugs kill cells (cancerous or not) are still poorly understood. Professor Thanos Halazonetis’ laboratory in the Department of Molecular and Cellular Biology at the UNIGE Faculty of Science, in collaboration with FoRx Therapeutics, has dissected the mechanisms of action of PARP inhibitors. The scientists used two classes of PARP inhibitors that identically block PARP’s enzymatic activity – that is, the synthesis of the sugar chain that serves as an alarm signal – but do not trap PARP on DNA with the same strength. The team observed that both inhibitors kill cancer cells with the same efficiency, but that the inhibitor that weakly binds PARP to DNA is much less toxic to healthy cells.

    A warning signal to prevent DNA strand collisions

    ‘We discovered that PARP not only acts as an alarm signal to recruit DNA repair proteins, it also intervenes when abnormal DNA structures are formed as a result of collisions between different machineries that read or copy the same portion of DNA.”


    Michalis Petropoulos, post-doctoral fellow in the Department of Molecular and Cellular Biology at the UNIGE Faculty of Science and first author of the study

    When using anti-PARP treatment, this warning signal to prevent collisions is not triggered. These collisions between the machinery will lead to an increase in DNA lesions, which cannot be repaired in cancer cells, because they lack the BRCA repair proteins. The second activity of PARP treatments, resulting in tight binding, aka trapping, of PARPs on DNA also leads to DNA damage that needs to be repaired by cells. But this repair is not mediated by the BRCA repair proteins and, as a result, both normal and cancer cells are killed.

    ”We therefore discovered that inhibition of the enzyme activity is sufficient to kill cancer cells, whereas trapping – when PARP is strongly bound to DNA – kills the normal cells as well, and therefore is responsible for the toxicity of these drugs,” summarizes Thanos Halazonetis, head of the study. ”This knowledge will make it possible to develop safer PARP inhibitors that inhibit PARP’s enzymatic activity without trapping it on DNA”.

    Source:

    Journal reference:

    Petropoulos, M., et al. (2024). Transcription–replication conflicts underlie sensitivity to PARP inhibitors. Nature. doi.org/10.1038/s41586-024-07217-2.

    [ad_2]

    Source link